GlaxoSmithKline PLC (GSK)

40.90
NYSE : Health Care
Prev Close 40.78
Day Low/High 40.64 / 40.93
52 Wk Low/High 37.20 / 45.58
Avg Volume 3.18M
Exchange NYSE
Shares Outstanding 2.46B
Market Cap 100.28B
EPS 0.50
P/E Ratio 23.44
Div & Yield 2.30 (5.60%)

Latest News

Glaxo Stock Slumps as Investors Eye Advair Generics

Glaxo Stock Slumps as Investors Eye Advair Generics

Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline posted stronger-than-expected first quarter earnings and kept its full year profit and revenue figures in place as it awaits potential rivals to is Advair respiratory treatment.line

Can Anything Dent the Fox News Brand?

Can Anything Dent the Fox News Brand?

Two sexual harassment scandals might devastate other brands, but not so with Fox News.

These Stocks Are Showing Red Flags -- Here's When to Sell

These Stocks Are Showing Red Flags -- Here's When to Sell

You don't want to own these four 'toxic stocks'.

4 Stocks Are Showing Red Flags -- Here's When to Sell

4 Stocks Are Showing Red Flags -- Here's When to Sell

You don't want to own these four 'toxic stocks'.

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa was seeking election of three nominees at the pharmaceutical company that the activist claims is being run for management's benefit.

How Badly Is the Bill O'Reilly Situation Hurting 21st Century Fox?

How Badly Is the Bill O'Reilly Situation Hurting 21st Century Fox?

As advertiser boycotts of 'The O'Reilly Factor' continue to grow, so do analysts' concerns about the network's bottom line. But the impact may be muted for now.

Murdochs Get European Approval for Sky Deal Despite Sexual Claims Against O'Reilly

Murdochs Get European Approval for Sky Deal Despite Sexual Claims Against O'Reilly

21st Century Fox still needs to get approval from U.K. regulators before it can close the $14.2 billion acquisition of the satellite TV and internet provider.

At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims

At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims

The list of major advertisers that have either removed their ads completely or shifted them away from Fox's popular primetime program, 'The O'Reilly Factor,' continues to grow.

GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.

GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.

GlaxoSmithKline is recalling some asthma inhalers due to a leak in the pump.

New Sexual and Racial Claims Against Fox News Increase Pressure on Younger Murdochs

New Sexual and Racial Claims Against Fox News Increase Pressure on Younger Murdochs

Several advertisers have withdrawn from Bill O'Reilly's show following A New York Times report tying him to payouts to quiet allegations of sexual harassment. Meanwhile, new racial cases have emerged.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Google's 'Very Very Very Small' Advertising Problem Is Anything but for Some Marketers

Google's 'Very Very Very Small' Advertising Problem Is Anything but for Some Marketers

Among others, GlaxoSmithKline, which suspended its ads from YouTube, said it will continue boycotting the site until Google can fully resolve its issues with offensive content.

VBI Vaccines Emerges as Strong Biotech Stock

VBI Vaccines Emerges as Strong Biotech Stock

Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.

GlaxoSmithKline Continues to Strengthen

GlaxoSmithKline Continues to Strengthen

Technical indicators suggest GSK can see further significant gains in 2017.

Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content

Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content

Google faces some tough decisions as the boycott of its YouTube network by advertisers continues to grow.

Why Google Has to Definitively Address Its Offensive Content Problem

Why Google Has to Definitively Address Its Offensive Content Problem

The Alphabet unit can't just 'put a band aid' on advertisers' concerns, lest it risk damaging its second-largest source of advertising revenue growth.

More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.

Still Bullish on GlaxoSmithKline

Still Bullish on GlaxoSmithKline

After another technical look at GSK, this FTSE component is still going strong.

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

GlaxoSmithKline, Chubb, XPO Logistics, FedEx: 'Mad Money' Lightning Round

GlaxoSmithKline, Chubb, XPO Logistics, FedEx: 'Mad Money' Lightning Round

Jim Cramer is bullish on GlaxoSmithKline, Chubb, XPO Logistics and FedEx; he's bearish on ZTO Express and Advanced Semiconductor Engineering.

GSK's Board Faces Pressure Over Incoming CEO's Pay

GSK's Board Faces Pressure Over Incoming CEO's Pay

GlaxoSmithKline faces a rebellion from shareholders over the pay package of its incoming CEO Emma Walmsley, the U.K.'s top businesswoman

These Are the Signs of a Healthy Stock Market: Cramer's 'Mad Money' Recap (Thursday, 3/2/2107)

These Are the Signs of a Healthy Stock Market: Cramer's 'Mad Money' Recap (Thursday, 3/2/2107)

It wasn't an up day for the markets, but it's great news when a critical IPO goes off without any major problems, says Jim Cramer.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Why I'm Optimistic About GlaxoSmithKline

Why I'm Optimistic About GlaxoSmithKline

Check out GSK's well developed base pattern.

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled...